ScreenerHero

ADIL Adial Pharmaceuticals, Inc.

NAS · US · Healthcare · Biotechnology · adial.com
3.990USD+0.25%Mkt Cap: 10.48M $P/E: —

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap10.48M USD
Enterprise Value20.27M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-7.98M USD
Revenue/Share—
Last Price3.990 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees5
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.53
PEG—
EV/EBITDA-1.76
EV/Revenue—
P/S—
P/B-0.27
EPS (TTM)-18.89
EPS (Forward)-7.45
52W Range
1.31028% of range10.75
52W High10.75 USD
52W Low1.310 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-151.18%
ROA-119.54%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-6.49M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-37.53%
Net Debt-28.71M USD
Net Debt/EBITDA2.50
Balance Sheet
Debt/Equity—
Current Ratio5.63
Quick Ratio5.61
Book Value/Sh-14.62 USD
Cash/Share10.93 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateFeb 6, 2026
Analyst Consensus
Rating—
Target (Mean)8.333 USD
Upside (mean)+108.9%
Target Range6.000 USD – 11.00 USD
6.000+108.9% to mean11.00
# Analysts3
Ownership
Shares Out.2.63M
Float2.11M
Insiders7.08%
Institutions29.85%
Short Interest
Short Ratio3.1d
Short % Float8.03%
Short % Out.8.00%
Shares Short209.98K
Short (prev mo.)231.71K
Technical
SMA 504.809 (-17.0%)
SMA 2003.427 (+16.4%)
Beta1.50
S&P 52W Chg16.45%
Avg Vol (30d)55.37K
Avg Vol (10d)43.16K
Technical Indicators
RSI (14)42.2
MACD-0.2252
MACD Signal-0.1309
MACD Hist.-0.0943
BB Upper6.156 USD
BB Middle4.620 USD
BB Lower3.084 USD
BB Width66.48%
ATR (14)0.5167 USD
Vol Ratio (20d)0.09x